SYRS
Syros Pharmaceuticals, Inc.
Healthcare · Biotechnology · PNK
$0.00
Data: 2026-05-22
✗ ETHICAL FAIL
MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$5,366
Total market value of the company
0.00
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Syros Pharmaceuticals, Inc.
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
1,122,363.0% FAIL
Debt must be below 33% of total assets
Cash Ratio
1,086,004.5% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
-99.4%
Historical annualised return based on price data
Days in State
1
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-12-02 | SIMONIAN NANCY A | Director | 37,070 | $10,016 | |
| 2024-11-25 | SIMONIAN NANCY A | Director | 134,713 | $35,739 | |
| 2024-11-19 | QUIRK GERALD E. | Officer | 46,657 | $12,915 | |
| 2024-11-18 | ROTH DAVID A M.D. | Officer | 12,099 | $2,382 | |
| 2024-11-18 | STEPHENS KRISTIN | Officer | 36,133 | $7,949 | |
| 2024-11-18 | CHEE CONLEY | Chief Executive Officer | 134,797 | $26,932 | |
| 2024-11-18 | HAAS JASON | Chief Financial Officer | 137,803 | $28,980 | |
| 2024-10-31 | SIMONIAN NANCY A | Director | 40,125 | — | |
| 2024-10-31 | ROTH DAVID A M.D. | Officer | 18,875 | — | |
| 2024-10-31 | STEPHENS KRISTIN | Officer | 17,000 | — |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-22